Orladeyo’s FDA approval Heralds New Funding for BioCryst
On December 3rd, BioCryst Pharmaceuticals announced that the Food and Drug Administration (FDA) approved Orladeyo (Berotralstat) as a preventative treatment for attacks of hereditary angioedema (HAE) in adult and pediatric …
Read More